Standout Papers

Sacituzumab G... 1978 2026 1994 2010 575
  1. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer (2019)
    Aditya Bardia, Ingrid A. Mayer et al. New England Journal of Medicine
  2. Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning (1978)
    David M. Goldenberg, Frank H. DeLand et al. New England Journal of Medicine
  3. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* (2015)
    David M. Goldenberg, Thomas M. Cardillo et al. Oncotarget

Immediate Impact

14 by Nobel laureates 7 from Science/Nature 81 standout
Sub-graph 1 of 21

Citing Papers

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 Standout
T-cell-engaging bispecific antibodies in cancer
2023 Standout

Works of David M. Goldenberg being referenced

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
2022
Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells
2017
and 2 more

Author Peers

Author Last Decade Papers Cites
David M. Goldenberg 16147 10664 3910 6919 733 27.7k
Wim J.G. Oyen 12539 7098 1025 5731 672 30.0k
Peter Johnson 3695 7350 7598 5422 604 23.3k
Andrew M. Scott 7201 5868 688 6415 630 20.7k
Jeffrey Schlom 9770 18774 1928 12433 775 38.2k
Otto C. Boerman 8607 5613 660 6165 479 21.6k
Oliver W. Press 6780 7534 6788 3076 384 17.5k
Theodore S. Lawrence 7740 8394 852 8330 611 27.1k
Giuseppe Curigliano 3603 15507 2209 5310 828 25.2k
Soldano Ferrone 5893 13716 1243 10404 858 34.4k
Silvia C. Formenti 4026 15199 1545 4992 346 26.4k

All Works

Loading papers...

Rankless by CCL
2026